Conference data: Phase III Orient RCT of sintilimab plus bevacizumab as first-Line treatment in advanced hepatocellular carcinoma

An interim analysis of the study reported improved overall survival with sintilimab plus bevacizumab vs sorafenib (median OS not reached vs 10.4 months) and progression free survival (4.6 vs 2.8 months; HR 0.5 95%CI; P<0.0001) in 571 patients.

Biospace Inc.